Evidence map›Paper›PMID 35889441›Full record

ArticleMolecules (Basel, Switzerland)2022

Antiproliferative Ruthenium Complexes Containing Curcuminoid Ligands Tested In Vitro on Human Ovarian Tumor Cell Line A2780, towards Their Capability to Modulate the NF-

Janka Leskovská, Natalia Miklášová, Paul Milan Kubelac, Patriciu Achimaş-Cadariu, Jindra Valentová, Mário Markuliak, Eva Fischer-Fodor

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Curcumin in ovarian cancer: mechanistic insights and translational potential.Medical oncology (Northwood, London, England) · 2026
    Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Janka LeskovskáDepartment of Chemical Theory of Drugs, Faculty of Pharmacy, Comenius University in Bratislava, Kalinčiakova 8, 83104 Bratislava, Slovakia.
Natalia MiklášováDepartment of Chemical Theory of Drugs, Faculty of Pharmacy, Comenius University in Bratislava, Kalinčiakova 8, 83104 Bratislava, Slovakia.ORCID 0000-0002-8682-1760
Paul Milan KubelacInstitute of Oncology "Prof.Dr.I.Chiricuta", RO-400015 Cluj-Napoca, Romania.ORCID 0000-0001-7957-9796
Patriciu Achimaş-CadariuInstitute of Oncology "Prof.Dr.I.Chiricuta", RO-400015 Cluj-Napoca, Romania.
Jindra ValentováDepartment of Chemical Theory of Drugs, Faculty of Pharmacy, Comenius University in Bratislava, Kalinčiakova 8, 83104 Bratislava, Slovakia.
Mário MarkuliakDepartment of Chemical Theory of Drugs, Faculty of Pharmacy, Comenius University in Bratislava, Kalinčiakova 8, 83104 Bratislava, Slovakia.
Eva Fischer-FodorInstitute of Oncology "Prof.Dr.I.Chiricuta", RO-400015 Cluj-Napoca, Romania.ORCID 0000-0002-0898-0547
Comenius University Bratislava · SKIuliu Hațieganu University of Medicine and Pharmacy · ROInstitute of Oncology Prof. Dr. Ion Chiricuta · RO

Funding

Ministry of Research and Innovation, CNCS - UEFISCDI PN-III-P4-ID-PCCF-2016-0142Scientific Grant Agency of Slovak Republic VEGA 1/0145/20
6 · The paper itself

Abstract

So far, the polyphenolic components of turmeric have shown a significant pharmacological preventative activity for a wide spectrum of diseases, including oncological disorders. This type of natural product could be of great interest for the inhibition of cancer cell proliferation, displaying less side effects in comparison to classical chemotherapeutics. The poor bioavailability and quick metabolism of such natural compounds require new investigative methods to improve their stability in the organisms. A synthetic approach to increase the efficiency of curcuminoids is to coordinate them to metals through the beta-dicarbonyl moiety. We report the synthesis and the biological attempts on human ovarian carcinoma A2780 of ruthenium(II) complexes

Indexed as

Antineoplastic AgentsCurcuminOvarian NeoplasmsRutheniumCell Line, TumorDiarylheptanoidsFemaleFibroblast Growth Factor 2HumansLigandsMatrix Metalloproteinase 9Antineoplastic AgentsCurcuminDiarylheptanoidsFibroblast Growth Factor 2LigandsMatrix Metalloproteinase 9Rutheniumbisdemethoxycurcumin (BDMC)cytotoxicityFGF-2MMP-9NF-κBruthenium(II) complexessyringaldehyde curcumin

Identifiers

PMID35889441
PMCPMC9322753
OpenAlexW4285730590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.